Archive

HIGHLIGHTS

 
LSP leads $38.5 Million Series B Financing in DNA Script
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.   Paris, May 16, 2019 — [...]
 
LSP’s portfolio company Binx Health Receives CE Mark for Rapid Chlamydia and Gono...
Multiplex Test Panel for binx io® Point-of-Care Platform Positioned to Radically Reduce Time to Treatment, Expand Access to Care   May [...]
 
Okairos winner of the Swiss Biotech Success Stories Awards 2018/19
Basel, Switzerland, May 7, 2019 – LSP is pleased to announce that Okairos has been recognised as one of the winners of the Swiss Biotech Success [...]
 
LSP co-leads $50 million Series A financing in SNIPR BIOME
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announc[...]
 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUT[...]
 
EMA making its first public appearance at our conference
The timing was perfect – the EMA would complete its move to Amsterdam in March and LSP would host its increasingly popular healthcare conference,[...]
 
LSP leads €28 million Series B financing in Atlantic Therapeutics
Amsterdam, the Netherlands, January 7, 2019 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investme[...]
 
LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5%
For more insight into our returns and investment strategy please read our just published March Monthly LSP Life Sciences Fund report. To see the fu[...]
 
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Liste...
Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis[...]
 
LSP's portfolio company GTX Medical on Dokters van Morgen
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ways to treat spinal cord injuries. From Minute 19 - 35, you can see L[...]
 
Amarin – a story close to our hearts, Keynote speaker at BioCapital
Keynote speaker CEO John Thero telling this remarkable story on our BioCapital conference last week   When we first encountered Amarin Cor[...]
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser...
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discover[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 

2019


Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update
UTRECHT, The Netherlands, May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative [...]
argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology
Breda, the Netherlands / Ghent, Belgium, May 28, 2019 – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatme [...]
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Program addressing first-in-class targets Highlights formation of two global therapeutic franchises in neur [...]
Kiadis Submits Response to the European Medicines Agency's Day 180 Second List of Outstanding Issues
Amsterdam, The Netherlands, May 22, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitte [...]
LSP leads $38.5 Million Series B Financing in DNA Script
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.   Paris, May 16, 2019 — DNA Script today announced an oversubscribed Series B fundraising of $ [...]
argenx reports first quarter 2019 financial results and provide business update
Breda, the Netherlands / Ghent, Belgium, May 9, 2019 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP leads $38.5 Million Series B Financing in DNA Script
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.   Paris, May 16, 2019 — DNA Script today announced an oversubscribed Series B fundraising of $[...]
 
LSP’s portfolio company Binx Health Receives CE Mark for Rapid Chlamydia and Gonorrhea Test for Mass Markets
Multiplex Test Panel for binx io® Point-of-Care Platform Positioned to Radically Reduce Time to Treatment, Expand Access to Care   May 1, 2019 (BOSTON, MA) – Binx Health, the pioneer in anywhere care tod[...]
 
Okairos winner of the Swiss Biotech Success Stories Awards 2018/19
Basel, Switzerland, May 7, 2019 – LSP is pleased to announce that Okairos has been recognised as one of the winners of the Swiss Biotech Success Stories Awards 2018/ 2019.  Okairos (now GlaxoSmithKline) has dev[...]
 
LSP co-leads $50 million Series A financing in SNIPR BIOME
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by LSP and existing investor L[...]
 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights from SK Biopharmaceuticals to develop and commercialize Cenobamate in[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe[...]
 
EMA making its first public appearance at our conference
The timing was perfect – the EMA would complete its move to Amsterdam in March and LSP would host its increasingly popular healthcare conference, BioCapital Europe, in the same month. Having a representative from EM[...]
 
LSP leads €28 million Series B financing in Atlantic Therapeutics
Amsterdam, the Netherlands, January 7, 2019 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Atlantic Therapeutics, the Irish medical technology company deve[...]
 
LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5%
For more insight into our returns and investment strategy please read our just published March Monthly LSP Life Sciences Fund report. To see the full report click here. 
 
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis Proceeds of approxim[...]
 
LSP's portfolio company GTX Medical on “Dokters van Morgen”
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ways to treat spinal cord injuries. From Minute 19 - 35, you can see LSP porfolio company GTX Medical founder Grégoire Courtine giving insi[...]
 
Amarin – a story close to our hearts, Keynote speaker at BioCapital
Keynote speaker CEO John Thero telling this remarkable story on our BioCapital conference last week   When we first encountered Amarin Corporation it was a microcap company incorporate in Dublin. Despite the [...]
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 

2019


Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update
UTRECHT, The Netherlands, May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative [...]
argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology
Breda, the Netherlands / Ghent, Belgium, May 28, 2019 – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatme [...]
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Program addressing first-in-class targets Highlights formation of two global therapeutic franchises in neur [...]
Kiadis Submits Response to the European Medicines Agency's Day 180 Second List of Outstanding Issues
Amsterdam, The Netherlands, May 22, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitte [...]
LSP leads $38.5 Million Series B Financing in DNA Script
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.   Paris, May 16, 2019 — DNA Script today announced an oversubscribed Series B fundraising of $ [...]
argenx reports first quarter 2019 financial results and provide business update
Breda, the Netherlands / Ghent, Belgium, May 9, 2019 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview